Prognostic significance of KIF2A and KIF20A expression in human cancer
Open Access
- 1 November 2019
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 98 (46), e18040
- https://doi.org/10.1097/md.0000000000018040
Abstract
Background: The kinesin family (KIF) is reported to be aberrantly expressed and significantly correlated with survival outcomes in patients with various cancers. This meta-analysis was carried out to quantitatively evaluate the prognostic values of partial KIF members in cancer patients. Methods: Two well-known KIF members, KIF2A and KIF20A, were investigated to evaluate their potential values as novel prognostic biomarkers in human cancer. A comprehensive literature search was carried out of the PubMed, EMBASE, Cochrane Library, and Web of Science databases up to April 2019. Pooled hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the association of KIF2A and KIF20A expression with overall survival (OS) and clinicopathological parameters. Results: Twenty-five studies involving 7262 patients were finally incorporated, including nine about KIF2A and sixteen about KIF20A. Our results indicated that patients with high expression of KIF2 and KIF20A tended to have shorter OS than those with low expression (HR = 2.23, 95% CI = 1.87–2.65, P < .001; HR = 1.77, 95% CI = 1.57–1.99, P < .001, respectively). Moreover, high expression of these 2 KIF members was significantly associated with advanced clinical stage (OR = 1.98, 95% CI: 1.57–2.50, P < .001; OR = 2.63, 95% CI: 2.03–3.41, P < .001, respectively), positive lymph node metastasis (OR = 2.32, 95% CI: 1.65–3.27, P < .001; OR = 2.13, 95% CI: 1.59–2.83, P < .001, respectively), and distant metastasis (OR = 2.20, 95% CI: 1.21–3.99, P = .010; OR = 5.25, 95% CI: 2.82–9.77, P < .001, respectively); only high KIF20A expression was related to poor differentiation grade (OR = 1.82, 95% CI: 1.09–3.07, P = .023). Conclusions: High expression of KIF2 and KIF20A in human cancer was significantly correlated with worse prognosis and unfavorable clinicopathological features, suggesting that these 2 KIF members can be used as prognostic biomarkers for different types of tumors. PROSPERO REGISTRATION NUMBER: CRD42019134928.Keywords
Funding Information
- 23456 Talent Project of Henan Provincial People's Hospital (ZC23456005)
- Henan Provincial Innovative Talents Project-Leading Talents (CYQ20160243)
- Henan Provincial Innovative Talents Project-Leading Talents 2017 (CYQ20170165)
This publication has 58 references indexed in Scilit:
- Clinical analysis of selected complement-derived molecules in human adipose tissueJournal of Translational Medicine, 2013
- Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancerJournal of Translational Medicine, 2013
- The role of kinesin family proteins in tumorigenesis and progressionCancer, 2010
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Overexpression of Kif2a promotes the progression and metastasis of squamous cell carcinoma of the oral tongueOral Oncology, 2010
- The Kinesin-13 Proteins Kif2a, Kif2b, and Kif2c/MCAK Have Distinct Roles during Mitosis in Human CellsMolecular Biology of the Cell, 2007
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Efficient Mitosis in Human Cells Lacking Poleward Microtubule FluxCurrent Biology, 2005
- Kinesin Superfamily Protein 2A (KIF2A) Functions in Suppression of Collateral Branch ExtensionCell, 2003
- The Human Kinesin-Like Protein RB6K Is under Tight Cell Cycle Control and Is Essential for CytokinesisMolecular and Cellular Biology, 2001